Abbott Laboratories
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert B. Ford
- Full Time Employees
- 115,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 100 Abbott Park Road Abbott Park IL United States 60064-6400
- IPO Date
- Mar 1, 1937
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Company News
These 12 stocks are good bets to beat the 10-year Treasury over the next decade
99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp
Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings
Abbott Touts Favorable Outcomes In Cardiovascular Device Trials
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Best Dividend Aristocrats For November 2026
U.S. politician makes super suspicious Big Tech stock trades
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead
Abbott Laboratories $ABT Shares Purchased by Evergreen Capital Management LLC
This Dividend King Just Announced Great News for Investors
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott Laboratories: A New Growth Story Takes Shape